Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

209 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
In vivo tracking of dendritic cells in patients with multiple myeloma.
Prince HM, Wall DM, Ritchie D, Honemann D, Harrrison S, Quach H, Thompson M, Hicks R, Lau E, Davison J, Loudovaris M, Moloney J, Loveland B, Bartholeyns J, Katsifis A, Mileshkin L. Prince HM, et al. J Immunother. 2008 Feb-Mar;31(2):166-79. doi: 10.1097/CJI.0b013e31815c5153. J Immunother. 2008. PMID: 18481386
Compliance with PET acquisition protocols for therapeutic monitoring of erlotinib therapy in an international trial for patients with non-small cell lung cancer.
Binns DS, Pirzkall A, Yu W, Callahan J, Mileshkin L, Conti P, Scott AM, Macfarlane D, Fine BM, Hicks RJ; OSI3926g Study Team. Binns DS, et al. Eur J Nucl Med Mol Imaging. 2011 Apr;38(4):642-50. doi: 10.1007/s00259-010-1665-0. Epub 2011 Jan 5. Eur J Nucl Med Mol Imaging. 2011. PMID: 21207024 Clinical Trial.
Changes in 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non-small cell lung cancer treated with erlotinib.
Mileshkin L, Hicks RJ, Hughes BG, Mitchell PL, Charu V, Gitlitz BJ, Macfarlane D, Solomon B, Amler LC, Yu W, Pirzkall A, Fine BM. Mileshkin L, et al. Clin Cancer Res. 2011 May 15;17(10):3304-15. doi: 10.1158/1078-0432.CCR-10-2763. Epub 2011 Mar 1. Clin Cancer Res. 2011. PMID: 21364032 Clinical Trial.
Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors.
Infante JR, Camidge DR, Mileshkin LR, Chen EX, Hicks RJ, Rischin D, Fingert H, Pierce KJ, Xu H, Roberts WG, Shreeve SM, Burris HA, Siu LL. Infante JR, et al. Among authors: mileshkin lr. J Clin Oncol. 2012 May 1;30(13):1527-33. doi: 10.1200/JCO.2011.38.9346. Epub 2012 Mar 26. J Clin Oncol. 2012. PMID: 22454420 Clinical Trial.
Pertuzumab and erlotinib in patients with relapsed non-small cell lung cancer: a phase II study using 18F-fluorodeoxyglucose positron emission tomography/computed tomography imaging.
Hughes B, Mileshkin L, Townley P, Gitlitz B, Eaton K, Mitchell P, Hicks R, Wood K, Amler L, Fine BM, Loecke D, Pirzkall A. Hughes B, et al. Oncologist. 2014 Feb;19(2):175-6. doi: 10.1634/theoncologist.2013-0026. Epub 2014 Jan 23. Oncologist. 2014. PMID: 24457379 Free PMC article. Clinical Trial.
209 results